By Marie Rosenthal, MS
SEATTLE—A two-drug maintenance regimen of dolutegravir (DTG; Tivicay, ViiV) and rilpivirine (RPV; Edurant, Janssen) appear to be safe and effective as maintenance therapy for patients with HIV, according to data presented at the 2017 Conference on Retroviruses and Opportunistic Infections (abstract 44LB).
“The requirement of lifelong treatment for HIV infection has highlighted a need to minimize cumulative drug exposure,” said Josep M. Llibre, MD, an